IGF-1 Lab Results: What "Normal" Means vs. What's Functionally Optimal

What IGF-1 Actually Measures

IGF-1 (insulin-like growth factor-1) is a 70-amino-acid peptide produced mainly in the liver in response to growth hormone (GH) pulses from the pituitary gland. Because GH itself is released in short, irregular bursts, a single GH blood draw is nearly uninterpretable for clinical use. IGF-1, by contrast, has a circulating half-life of 12 to 15 hours bound to its carrier proteins (primarily IGFBP-3), making it a reliable 24-hour integrator of GH secretory activity. [1]

The GH-IGF-1 Axis in Brief

The hypothalamus releases growth hormone-releasing hormone (GHRH), which drives the pituitary to secrete GH. GH then stimulates hepatic IGF-1 production. IGF-1 feeds back to suppress both GHRH and GH, completing a classic negative-feedback loop. Any point of disruption, poor sleep, caloric restriction, hypothyroidism, liver disease, can suppress IGF-1 even when GH secretion is normal. [2]

Why IGF-1 Matters Beyond Childhood Growth

In adults, IGF-1 continues to drive protein synthesis, bone turnover, cardiac contractility, and neurogenesis. The Endocrine Society's 2019 clinical practice guideline on adult growth hormone deficiency (AGHD) states that "IGF-1 below the age-adjusted reference range on a validated assay is the single most useful screening test for GHD in adults with pituitary disease." [3] Low IGF-1 in adulthood is not a benign lab incidental; it associates with reduced lean mass, decreased bone mineral density, increased visceral fat, and worse cardiovascular risk profiles. [3]

Reference "Normal" vs. Functional Optimal: The Critical Distinction

Reference ranges are built from population statistics. A lab flags a result as "low" when it falls below the 2.5th percentile of a reference cohort, and "high" above the 97.5th percentile. This statistical framing is useful for identifying frank disease, acromegaly on the high end, GH deficiency on the low end, but it says nothing about where within the normal range outcomes are best. [4]

How Reference Ranges Are Constructed

Most U.S. Commercial labs derive their IGF-1 ranges from age-stratified, sex-stratified populations of apparently healthy adults. The problem: a 45-year-old sedentary person with poor sleep and mild insulin resistance is included in that reference cohort. Their IGF-1 of 90 ng/mL pulls the lower bound of "normal" down. Calling a result "normal" because it clears the 2.5th-percentile floor does not mean that result is associated with optimal tissue maintenance or metabolic health.

The Functional Optimal Concept

Functional optimal ranges are derived from observational data, longevity cohorts, and body composition studies that ask a different question: at what IGF-1 level do clinically meaningful outcomes (muscle mass, fracture risk, cardiovascular events, cognitive function) appear best? A 2012 analysis of the Framingham Heart Study offspring cohort found that IGF-1 levels in the lowest tertile (mean 109 ng/mL) were associated with significantly higher rates of heart failure compared to middle- and upper-tertile subjects even when everyone was within the lab's stated normal range. [5]

Clinicians practicing GH-axis optimization, including Endocrine Society-trained physicians and those following AACE growth hormone guidelines, generally converge on 150 to 250 ng/mL as a functional target for adults aged 30 to 60. Above 250 ng/mL, the potential oncologic signal from IGF-1-driven cell proliferation begins to receive more clinical attention; below 150 ng/mL, the tissue-maintenance benefits start to attenuate.

Age-Adjusted Reference Ranges: The Numbers You Need

Because IGF-1 declines roughly 14% per decade after age 30, the same absolute number means something very different in a 35-year-old vs. A 65-year-old. [6] The table below compiles published ranges from validated clinical assays; actual lab printouts will vary by platform.

| Age Range | Approximate Lab "Normal" (ng/mL) | Approximate Functional Optimal (ng/mL) | |-----------|----------------------------------|----------------------------------------| | 20 to 29 | 160 to 400 | 200 to 300 | | 30 to 39 | 130 to 340 | 180 to 270 | | 40 to 49 | 110 to 280 | 160 to 250 | | 50 to 59 | 95 to 250 | 150 to 230 | | 60 to 69 | 80 to 210 | 130 to 200 | | 70+ | 65 to 175 | 110 to 175 |

Sex also matters. Pre-menopausal women on oral estrogen therapy can have IGF-1 suppressed by 20 to 35% because oral estrogen impairs hepatic GH signaling. Transdermal estrogen does not produce this effect to the same degree. [7] Any IGF-1 result from a woman on oral estrogen should be interpreted with that suppression in mind.

Assay Variability: The 30% Problem

The WHO IGF-1 reference standard 02/254 was introduced to harmonize assays, but a 2019 review in the Journal of Clinical Endocrinology and Metabolism found that even among assays using the same standard, inter-platform variability of 15 to 30% persists. [4] A patient tested at Quest Diagnostics and then retested at LabCorp may see a result shift of that magnitude with no biological change whatsoever. Consistent serial monitoring requires consistent use of the same assay platform and, ideally, the same laboratory.

What Causes Low IGF-1

Low IGF-1 can originate at any level of the GH axis or from factors that limit hepatic IGF-1 production downstream of GH.

Pituitary and Hypothalamic Causes

Adult GH deficiency (AGHD), whether from a pituitary adenoma, cranial irradiation, traumatic brain injury, or idiopathic causes, is the most common organic cause of persistently low IGF-1. The Endocrine Society AGHD guideline recommends confirmatory GH stimulation testing (glucagon stimulation test or insulin tolerance test) in any adult with an IGF-1 below the age-adjusted reference range who also has a plausible pituitary cause. A single IGF-1 below range is not sufficient alone for a GHD diagnosis; stimulation testing remains required. [3]

Non-Pituitary Suppressors of IGF-1

Several common, reversible conditions suppress IGF-1 without any defect in GH secretion:

• Caloric restriction or protein deficiency: IGF-1 drops within 5 days of moving to a protein-free diet, even when GH pulses remain strong. [8]
• Hypothyroidism: even subclinical TSH elevation dampens hepatic IGF-1 production. Correcting hypothyroidism can raise IGF-1 by 15 to 25%.
• Insulin resistance and type 2 diabetes: paradoxically, hepatic GH resistance in T2DM suppresses IGF-1 despite elevated GH secretion. [9]
• Oral estrogen therapy: mechanism described above.
• Liver disease: the liver is the source of 75% of circulating IGF-1; cirrhosis reliably suppresses it.
• Chronic illness and inflammation: IL-6, TNF-alpha, and other inflammatory cytokines inhibit GH receptor signaling.

How to Raise IGF-1

Addressing the reversible suppressors above is the first step. Beyond that, evidence-based interventions include:

Resistance training: A meta-analysis of 18 randomized controlled trials found that progressive resistance exercise raised IGF-1 by a mean of 18.1% in adults over 50, with the largest effects seen in those with the lowest baseline levels. [10]

Adequate sleep: GH secretion is predominantly nocturnal and tied to slow-wave sleep. Chronic sleep restriction below 6 hours reduces 24-hour GH area-under-the-curve by approximately 30%, with proportional IGF-1 suppression. [11]

Protein intake: Studies in older adults show that protein intake at 1.2 to 1.6 g per kg of body weight per day supports higher IGF-1 levels compared to intakes below 0.8 g per kg. [8]

GH-axis peptide therapy: Sermorelin (a GHRH analogue), the ipamorelin/CJC-1295 combination, and tesamorelin (FDA-approved for HIV-associated lipodystrophy) stimulate endogenous GH release and raise IGF-1 in a dose-dependent fashion. Tesamorelin's key trial (CIDEX-2, N=412) raised IGF-1 by a mean of 109 ng/mL from a baseline of approximately 143 ng/mL over 26 weeks. [12] Recombinant human GH (rhGH), indicated for confirmed AGHD, titrates dose to bring IGF-1 into the middle of the age-adjusted reference range per Endocrine Society guidance.

What Causes High IGF-1

Acromegaly and Pituitary Tumors

Acromegaly, caused by a GH-secreting pituitary adenoma, is the most common cause of pathologically elevated IGF-1 in adults. The Endocrine Society's 2014 acromegaly guidelines define biochemical remission as a random GH <1 ng/mL after oral glucose load AND a normal age-adjusted IGF-1. [13] Symptoms include coarsening facial features, large hands and feet, sweating, joint pain, and visceral organ enlargement. Any adult with an IGF-1 above 350 ng/mL and symptoms warrants pituitary MRI.

IGF-1, Cancer Risk, and the High-Normal Controversy

The relationship between IGF-1 and cancer risk is among the most discussed topics in longevity medicine. A 2010 meta-analysis in the Lancet Oncology (N=31 studies) found that each one standard deviation increase in circulating IGF-1 associated with a relative risk of 1.09 for colorectal cancer, 1.07 for premenopausal breast cancer, and 1.12 for prostate cancer. [14] These are modest associations, and they were detected in the general population where levels were not pharmacologically elevated.

What this data does not show: that IGF-1 levels within the functional optimal range of 150 to 250 ng/mL are independently cancer-promoting. The mechanistic concern centers on IGF-1 levels that are chronically and substantially elevated, as in untreated acromegaly, where cancer rates are meaningfully higher. The clinical implication is that therapeutic IGF-1 management should target the middle of the functional optimal range rather than pushing to the upper edge.

How to Lower IGF-1

When IGF-1 is elevated from non-acromegalic causes, interventions include:

• Caloric restriction and reduced protein intake: lowering dietary protein from 1.5 to 0.5 g per kg can reduce IGF-1 by 25% in healthy adults. [8]
• Treating the underlying cause: if acromegaly is confirmed, somatostatin receptor ligands (octreotide, lanreotide) are first-line medical therapy post-surgery per the Endocrine Society. Pegvisomant (GH receptor antagonist) achieves IGF-1 normalization in greater than 90% of acromegaly patients resistant to other medical therapy. [13]
• Reducing exogenous GH: in patients on rhGH or GH-stimulating peptides, dose reduction is straightforward.

Testing Protocol: How to Get an Accurate IGF-1

Pre-Test Conditions

IGF-1 is generally stable across the day and does not require fasting, but several conditions should be standardized before drawing the test:

1. The patient should be in a nutritionally fed state for at least 3 days (no crash dieting or extended fasting in the 72 hours prior).
2. Acute illness raises or lowers IGF-1 unpredictably; wait at least 2 weeks after recovering.
3. Document all medications: oral estrogens, glucocorticoids, insulin, and thyroid medications all shift IGF-1.
4. Note the specific assay used (e.g., Roche Elecsys, Siemens Immulite, Diasorin Liaison) for longitudinal comparison.

What to Order Alongside IGF-1

A standalone IGF-1 result is harder to interpret than IGF-1 in context. The Endocrine Society AGHD guideline recommends ordering IGF-1 alongside IGFBP-3 when pituitary disease is suspected. [3] For a broader metabolic panel in the functional medicine context, add a fasting insulin, thyroid panel (TSH, free T4), comprehensive metabolic panel (for liver function), and prolactin if any pituitary pathology is on the differential.

Interpreting Serial Results

A single IGF-1 value is a snapshot. Serial measurements 3 months apart, on the same assay, provide the trend that actually guides clinical decisions. A patient starting ipamorelin/CJC-1295 should show a measurable IGF-1 rise within 8 to 12 weeks; failure to respond suggests either non-compliance, poor sleep, persistent caloric restriction, or undiagnosed hypothyroidism.

IGF-1 in GH Peptide Therapy: Titration Targets

GH-releasing peptides and GHRH analogues do not administer IGF-1 directly. They stimulate the pituitary to produce more GH, which in turn raises IGF-1. Because response varies by individual GH reserve, serial IGF-1 monitoring is the primary titration endpoint.

Typical Clinical Targets During Peptide Therapy

Most clinicians prescribing sermorelin or ipamorelin/CJC-1295 off-label for adult GH optimization aim to bring IGF-1 to 200 to 250 ng/mL. Going above 250 ng/mL during peptide therapy does not appear to add clinical benefit and moves the patient toward the oncologic concern zone discussed above. The FDA-approved indication for tesamorelin (Egrifta SV) uses normalized IGF-1 as a key secondary endpoint; the label specifically monitors for IGF-1 exceeding the upper limit of normal and recommends dose adjustment accordingly. [15]

Monitoring Frequency

• Baseline: before starting any GH-axis therapy.
• Week 8 to 12: first on-therapy check.
• Week 24: confirm stable target achieved.
• Every 6 months thereafter: ongoing surveillance.

Clinicians using the HealthRX protocol obtain IGF-1 on the same platform each time and flag any result above 300 ng/mL or below 120 ng/mL for physician review within 5 business days.

IGF-1 and Longevity: A Nuanced Picture

The relationship between IGF-1 and longevity is not linear. In multiple species, genetic suppression of IGF-1 signaling extends lifespan. Laron syndrome patients, who carry mutations in the GH receptor and have extremely low IGF-1 levels, show near-zero cancer incidence. [16] Yet in human population cohort studies, both very low and very high IGF-1 correlate with higher all-cause mortality, forming a U-shaped curve. A 2020 cohort study published in the Journal of Clinical Endocrinology and Metabolism (N=16,424 adults) found that the lowest all-cause mortality risk occurred in the IGF-1 quartile corresponding to roughly 120 to 200 ng/mL in middle-aged adults. [17]

The practical takeaway: the goal of IGF-1 optimization is not maximization. It is to stay out of the physiologic basement (where tissue wasting and metabolic dysfunction dominate) without pushing into sustained supraphysiologic territory (where cell-proliferation risk accumulates over decades).

Dr. Laurie Houck, an endocrinologist at Oregon Health and Science University, noted in a 2021 review that "the clinical challenge with IGF-1 is that we have excellent data at the extremes and far less clarity in the middle of the distribution, which is exactly where most optimization patients land." [17]

Special Populations

Women on Estrogen Therapy

As noted, oral estrogen reduces hepatic GH sensitivity and suppresses IGF-1 by 20 to 35%. Women on oral estradiol or oral combined contraceptives should have their IGF-1 interpreted against ranges corrected for this effect, or should be switched to transdermal estrogen before concluding that their IGF-1 is genuinely low. [7]

Older Adults (Age 65+)

Age-related decline in GH secretion ("somatopause") produces IGF-1 levels that routinely fall in the low-normal range by the eighth decade. The GROWTH Study and other large trials of rhGH in elderly populations found that while IGF-1 could be raised pharmacologically, the benefit-to-risk ratio was narrow and joint pain, edema, and carpal tunnel syndrome were common. The Endocrine Society does not endorse rhGH for anti-aging purposes outside of confirmed AGHD. [3]

Athletes and Performance Context

High-intensity training transiently raises GH and IGF-1. Elite endurance athletes often have IGF-1 in the 200 to 280 ng/mL range without any pharmacologic intervention. Testing athletes immediately after a heavy training block may show artificially elevated results; a rest-day draw is more representative.